@FierceBiotech: Merrimack wins expedited FDA OK for pancreatic cancer drug Onivyde. Report | Follow @FierceBiotech
@JohnCFierce: The $NK market cap is down to a meager $873M, debuted at $2.6B -- Still too much? Soon-Shiong magic sparkles not so shiny? | Follow @JohnCFierce
@DamianFierce: So I guess $SHPG's Lumena buyout didn't go so well. Story | More | Follow @DamianFierce
> The FDA signed off on Turing Pharmaceuticals' plan to take its drug for a rare epileptic disorder into Phase I, granting fast-track status to the program. More
> Oasmia Pharmaceutical raised $9 million in an IPO, pricing below its expected range. News
> GlaxoSmithKline ($GSK) CEO Andrew Witty said his company's focus on low-margin therapeutic areas will insulate it from the pricing controversy now raging in the U.S. Story
Medical Device News
@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Silk Road reels in $57M to commercialize its system for stroke prevention. Article | Follow @VarunSaxena2
@EmilyWFierce: Dx Digest: Roche notches molecular diagnostics sales win; Veracyte CEO lambastes CMS pricing proposals. Report | Follow @EmilyWFierce
> Congressman to introduce bill banning Bayer's Essure contraceptive device. More
> Swiss scientists reveal miniaturized patient monitoring device for ICU. Story
Pharma News
@FiercePharma: Asia's dengue epidemic highlights race for treatment, vaccine options. FiercePharmaAsia story | Follow @FiercePharma
@EricPFierce: Japan's Chugai says its mAb work with Roche means a need for a $309M API plant expansion. FiercePharmaManufacturing news | Follow @EricPFierce
@CarlyHFierce: ICYMI: We did an episode of @FierceBiotech Radio on biopharma's wacky Wednesday. More | Follow @CarlyHFierce
> Novartis wins European recs for a pair of new Cosentyx uses. Item
> Shire's not giving up on target Baxalta, it says amid Q3 beat. Article